The Lattice (Official 3DHEALS Podcast)

We talk with Adam Steggi about why minimally invasive medical devices are getting harder to manufacture, and why that manufacturing constraint now shapes what products can exist at all. Adam shares how Trail Labs built Ripple to deliver CNC-equivalent micro metal parts in stainless steel, then chose a parts-first business model to drive real adoption.
00:00:00 - Welcome And A Parts-First Thesis
00:01:20 - Founder Lessons From A First Startup
00:04:45 - Minimally Invasive Devices Hit Manufacturing Limits
00:09:36 - Why RILP Had To Be Invented
00:11:48 - Selling Parts Instead Of Printers
00:17:06 - RIPL Explained And Where It Wins
00:19:58 - Finding Customers And Building To Production
00:22:50 - Unit Economics Versus CNC And MIM
00:27:19 - Scaling Challenges And The 2027 Goal
00:29:50 - Disclaimer And Closing

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

Healthcare loves innovation right up until the bill shows up. We sit down with Dr. Nayumi Nathan (Naomi), a medical doctor turned public health and health economics leader, to unpack why medical 3D printing and additive manufacturing are often ready before the healthcare system is. If you’ve ever wondered why point-of-care 3D printing can thrive in one hospital and stall in another, the answer is usually not the printer. It is reimbursement, evidence, and policy.

We dig into how Mobility Goes Additive (MGA) builds a Europe-wide ecosystem that connects hospitals, MedTech companies, researchers, regulators, and industry partners to move from scattered pilots to real adoption. Naomi explains why the EU is uniquely complex for healthcare market access: health authority is national, so scaling custom medical devices, patient-specific implants, and hospital 3D printing programs means navigating 26+ reimbursement and governance environments. That reality changes how startups and scale-ups should plan timelines, partnerships, and investment needs.

The conversation gets concrete on what must happen next: registries, multi-center studies, and credible patient outcome data that can support evidence-based policy and sustainable payment models. We also talk advocacy, political champions, and why additive manufacturing needs “commitment followed by investment,” including scale-up funding, not just startup grants. Along the way, we reality-check bioprinting hype and share what it will take for patients to one day ask for a 3D printed knee like it’s normal.

If you care about the future of medical 3D printing in Europe and beyond, listen, subscribe, and share this with someone building in healthcare. After you listen, leave a review and tell us: what is the biggest barrier to adoption where you live?

YouTube: coming soon

Show notes: coming soon

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

Everyone wants to fund the next miracle drug. Jim West thinks differently. In this episode, the Associate Director of BioTools Innovator makes the case that life-science tools and diagnostics are the better risk-adjusted venture bet than many therapeutics: you trade the 100X biotech moonshot for a 5-to-10X return with better odds, little regulatory risk, and a roughly five-year horizon. He backs it with the accelerator's own numbers: 95% of the companies through its six cohorts are still operating or acquired, out of roughly 2,800 applications — and explains why focus (not technology) is what most tool founders get wrong, what strategic acquirers actually pay for, and why private equity and family offices are reshaping how these companies get funded.

Show notes

YouTube Recording

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

We talk with Erik Boelen, founder of Qase3D, about how medical 3D printing went from a regulatory free-for-all to a world where hospital print labs function as medical device manufacturers. We break down MDR, CE marking, ISO 13485, and how to stay compliant with a lean system engineers will actually use.
• The early “no rules” era and why proof of quality becomes unavoidable
• How MDR and CE marking work for standard medical devices
• Why custom-made devices can be CE-exempt yet still heavily regulated
• ISO 13485 as a process-focused QMS and where it helps most
• Building a lean, day-to-day QMS instead of a paperwork vault
• The MDR Portal approach and the value of lawyer-backed interpretation
• Practical triggers for when a growing lab should consider ISO 13485 certification

00:00:00 - Welcome To The Regulatory Reality
00:03:10 - MDR, CE Mark, And ISO 13485
00:06:30 - Making Implants Before Clear Rules
00:08:33 - What Custom Made Really Means
00:10:20 - From Engineer To Quality Builder
00:12:12 - A Lean QMS People Actually Use
00:17:33 - The MDR Portal And Lawyer Support
00:26:45 - Scaling Compliance Without Bureaucracy
00:30:40 - The Future Of Hospital 3D Labs
00:41:05 - How To Contact Erik
00:43:15 - Disclaimer

Show notes: https://3dheals.com/episode-127-lean-compliance-for-medical-3d-printing-with-erik-boelen/

YouTube: https://youtu.be/wR7TVN4WGno?si=pvQ-Fl7VJNgNRq7F

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

The real frontier in medical 3D printing isn't the printer — it's the material. In this 3DHEALS panel, five researchers, founders, and industry leaders map the shift from printing structure to printing function, and from lab-stage novelty toward regulated, investment-grade material systems spanning soft bioresins, bioactive ceramics, and titanium lattices.

Fabian Trumper (Arrakis Bio) argues that the best biomaterials are the ones our bodies already make, and explains how his team bio-manufactures True Human Collagen at industrial scale. Prof. Kamal Choudhary (Johns Hopkins) shows why AI is reshaping materials discovery — a "ChatGPT for materials scientists" — and why so much of the field still isn't reproducible. Dr. Andrew Weems (Resilient Medical) shares how a 3D-printed scaffold could finally modernize lumpectomy surgery for breast cancer patients. Ebrahim Yarali (MERLN, Maastricht University) reveals how geometry alone — architected "meta-biomaterials" and 4D printing — can steer stem cells toward bone or cartilage. And Dr. Scott Taylor (Poly-Med) breaks down absorbable polymers that dissolve into the body once healing is done. Moderated by Craig Rosenblum, President of Himed.

In this episode:

• Human vs. synthetic biomaterials — and what cells actually "notice"
• AI-designed materials and the reproducibility crisis
• Designing devices for the surgery we already do
• 4D printing and geometry as a biological signal
• A live debate: can AI and lab models replace animal testing?

Whether you're a researcher, founder, or investor, this is a fast, opinionated tour of where medical materials are heading next.

🎥 Watch the full session and explore more 3DHEALS events: https://3dheals.com/biomaterials-frontier/

00:00:00 - Welcome And 3D Heals Missions
00:01:58 - Event Setup And Sponsor Context
00:04:08 - Absorbable Polymers And Degradation Design
00:10:07 - Pore Size And Surface Area Effects
00:12:40 - True Human Collagen For Regeneration
00:23:08 - Collagen Q&A On Regulation
00:28:58 - AI Tools For Materials Discovery
00:41:35 - AI Limits Data And Loop Closure
00:50:31 - Lumpectomy Scaffolds And Go To Market
01:01:47 - Academia Versus Startup Mindset
01:10:13 - Geometry Driven Bone Regeneration Scaffolds
01:24:11 - Acoustic Responsive And 4D Biomaterials
01:31:08 - Panel Debate On Animal Testing
01:37:39 - AI Hype Real Impact And Wish List
01:46:51 - Final Takeaways And Closing

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

A single university discovery can turn into a life-changing therapy, but only if someone can translate the science into a product, a company, and a development plan investors will actually fund. That is why we sat down with Mark from UCLA’s technology transfer and licensing team to demystify what happens after the lab result and before the biotech headline. We talk plainly about what a tech transfer office does, what it can license, and why “intellectual property” now stretches beyond patents into data, materials, and even carefully governed patient datasets.

We also zoom out to the policy foundation that made modern university commercialization possible: the Bayh-Dole Act. Mark explains how shifting IP ownership from the federal government to universities changed licensing outcomes and helped build the innovation ecosystem we now associate with US leadership in therapeutics. Along the way, we connect the dots to real UCLA impact, including major prostate cancer drugs and a licensed cure for ADA-SCID, and we unpack the tension founders often feel when a faculty inventor becomes a startup founder negotiating with their own campus.

Then we get tactical. We break down why big pharma often waits until risk is reduced, why faculty-led startups become the bridge, and how license strategy changes depending on whether you are building a therapeutic that needs exclusivity or a platform that benefits from nonexclusive access. Mark walks through diligence milestones, annual progress reporting, and the practical reality that most “shelving” is not malicious, it is a startup fighting for survival. If you care about biotech startups, university patents, and the future of the Los Angeles bioscience ecosystem, this conversation is a roadmap.

If this helped you see tech transfer differently, subscribe, share the episode with a founder or researcher, and leave a review telling us what part of the university-to-startup journey you want us to unpack next.

Show notes: coming soon

YouTube: coming soon

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

Gravity shapes every lab workflow we take for granted, and it may be the hidden constraint behind some of the hardest problems in regenerative medicine. We sit down with Dr. Michael Roberts, a microecologist who led bioregenerative life support research at NASA’s Kennedy Space Center and now serves as Chief Scientific Officer of the International Space Station National Laboratory, to talk about what microgravity is actually good for and why biomanufacturing in space is no longer just sci-fi.

YouTube: Pending

Show notes: Pending

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

A brain organoid that can learn to play Pac-Man sounds like a stunt until you realize what it represents: measurable learning, rewiring, and human-relevant neural function that animal models often fail to predict. We talk with Dr. Lowry Curley, founder of Luna LifeSci and former CEO and co-founder of Axosim (now 28 Bio), about why neuroscience drug development breaks so often and how NAMs are finally giving teams better tools to make safer calls earlier.

If you’re building in biotech, investing in drug discovery, or just trying to understand what replaces animal testing next, this conversation gives you a clear map of the technology, the incentives, and the milestones to watch. Subscribe, share this with a colleague, and leave a review with the biggest NAM question you want answered next.

Show notes: https://3dheals.com/episode-122-new-approach-methodologies-nams-with-dr-lowry-curley/

YouTube: https://youtu.be/suVxiYZgPVE

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

Absorbable biomaterials have transformed modern medicine, enabling implants, sutures, and drug-delivery systems that safely degrade once their function is complete. Dr. Rao S. Bezwada has helped shape the field of bioresorbable polymers for more than three decades. As the inventor of Monocryl®, the absorbable suture that has generated more than $2 billion in worldwide sales, and the holder of more than 150 U.S. patents, his innovations have influenced everything from surgical sutures to next-generation biomaterials. In this episode of The Lattice, Dr. Bezwada joins Dr. Jenny Chen to discuss the science behind bioresorbable polymers, the chemistry that controls how materials degrade, and what the next generation of resorbable biomaterials could make possible.

⚠️ Disclaimer:
This podcast is for educational and informational purposes only. The views expressed do not constitute engineering, medical, or financial advice. The technologies and procedures discussed may not be commercially available or suitable for every case. Always consult with a qualified professional.

YouTube video:

Show notes: https://3dheals.com/episode-121-absorbable-biomaterials-with-dr-rao-bezwada/

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

If you have ever wondered why dentistry can feel both high-tech and oddly hand-built at the same time, this conversation connects the dots. We talk with Dr. Nabeel Cajee, an oral implantologist in Newport Beach and faculty at Torque Academy and Implant Ninja School, about what it really takes to bring digital dentistry into daily patient care without turning your practice into a science project. From the earliest days of open-source 3D printing to today’s clinical workflows, he breaks the ecosystem down into what actually matters: data capture, dental CAD design, and fabrication with dependable post-processing.

If you care about dental 3D printing, chairside CAD/CAM, guided implant surgery, or the future of restorative dentistry, subscribe, share this with a colleague, and leave a review with your biggest question about digital workflows.

Show notes: https://3dheals.com/episode-119-where-is-dental-3d-printing-with-dr-nabeel-cajee/

YouTube Video: https://youtu.be/FOKQNpMJjb4?si=DImMXMXEiNH5oheH

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

Ossiform is on track to bring the first 3D printed resorbable bone implant to the US market. The company’s preclinical data showed full bone regeneration in six months. Monica Wellejus, Chief Commercial Officer of Ossiform, joins The Lattice to explain how a company built to personalize bone implants for craniomaxillofacial surgeries is pivoting to mass-produced bone implants for foot deformity, and why hospital finance teams, not just the surgeons, may decide whether this technology actually reaches patients.
⚠️ Disclaimer:
This podcast is for educational and informational purposes only. The views expressed do not constitute engineering, medical, or financial advice. The technologies and procedures discussed may not be commercially available or suitable for every case. Always consult with a qualified professional
00:00 Intro | Why 3D printed bone has not reached patients yet

02:08 Meet Monica Wellejus and Ossiform

05:41 How Ossiform prints bone substitutes using β-TCP ceramics

10:12 The long road to FDA clearance and U.S. market entry

14:03 Why Ossiform moved away from personalized implants

18:26 Listening to surgeons changed everything

23:47 Flatfoot reconstruction and Ossiform’s first clinical products

30:18 Fundraising, commercialization, and building a MedTech startup

38: 54 The hidden decision-makers in healthcare adoption

46:31 The future of bone regeneration, AI, and point-of-care manufacturing

Show notes: https://3dheals.com/episode-117-monica-wellejus-the-road-to-3d-printed-bone/
YouTube link: https://youtu.be/E8t35WzV7Eg?si=QH-XHfJDwihvqv6n

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

What does it take to invent a technology that didn't exist before?

In this episode, host Dr. Jenny Chen sits down with Professor Paul Dalton, the inventor of melt electrowriting (MEW) and one of the rare "triple threats" in science: an inventor, educator, and futurist. This is also a conversation about science, creativity, and why MEW isn't just a technology but a movement.

Paul takes us from a boredom-filled childhood on a rural farm outside Perth, Australia, to the ophthalmic research lab where he helped build artificial corneas that restored sight to blind patients. He shares the moment a failing electrospinning experiment pushed him toward MEW instead — and the "breathless" discovery under the microscope that became MEW.

Along the way, Jenny and Paul explore:

• What electrospinning and melt electrowriting actually are, explained in plain language
• Why MEW pulls fibers instead of pushing them, and how it prints at one-tenth of a teardrop per hour
• The decades-long pursuit of clinical applications
• The open-source "MEWron" printer is bringing MEW to labs for a fraction of the cost of commercial machines
• The two kinds of makers — builders vs. users — and where the community is heading
• Paul's advice for clinicians and newcomers entering biofabrication

Plus, a remarkable offer for listeners at the end of this episode.

🔗 Show notes

YouTube recording: Coming soon

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

This is our second episode recorded at the Materialise conference. Our guest for this episode is no other than the CEO of Materialise Brigitte de Vet-Veithen. It is a pleasure for me to be able to conduct this interview, because Materialise is such a legendary company that has spent 35 years building the software and services infrastructure behind patient-specific implants, surgical planning, and point-of-care manufacturing. We also got to know Brigitte as a person and the new leader of the company. Importantly, we covered the metrics that signal adoption, challenges to scale beyond the halo case, and her vision for the industry. In my opinion, this is perhaps one of the most important conversations for the medical 3D printing industry in 2026.

Highlights of this episode:

• Brigitte's journey from MedTech leadership to being the CEO at Materialise
• Why reimbursement is the clearest signal of adoption for medical 3D printing
• Building health economics evidence for patient-specific devices when every case is unique
• Helping physicians shift mindset toward pre-operative planning and new workflows
• The move from “3D printing company” to solution partner for specific clinical needs
• Why robots and surgical guides coexist, especially in ambulatory surgery centers
• How AI compresses lead times and expands access for trauma patients
• Mass personalization roadmap across orthopedics, CMF, pediatrics, respiratory, and structural heart
• Global adoption differences and why imaging availability sets the pace
• Investment priorities across education, evidence generation, R&D, and M&A

Please listen to the disclaimer at the end of this podcast.

Show Notes: https://3dheals.com/episode-114-interview-with-brigitte-de-vet-veithen-ceo-of-materialise/

YouTube: https://youtu.be/9PgME2RAmog?si=t-0X_DkrBdRg4MHe

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

This is one of two episodes we have recorded during our trip to Leuven Belgium for the Materialise 2026 Conference, focusing on 3D planning and 3D printing in hospitals. We talked with Dr. Tristan Remcharan about how pediatric cardiology imaging can become something you can literally hold, using 3D segmentation and 3D printing to make congenital heart disease easier to plan, teach, and explain. We also dig into the 2D versus 3D generational divide and the real-world funding hurdles that decide whether point-of-care 3D becomes routine care.

Show notes: https://3dheals.com/episode-113-how-3d-printing-explains-the-unexplainable-with-dr-tristan-ramcharan/

YouTube Video: https://youtu.be/eNUQWwJq5HM?si=3QhxXxvvUaEhO1MD

The 3D cardiac printing program at Birmingham Children's Hospital is funded by charitable donations.

To support Tristan's works directly: Birmingham Children's Hospital Charity — https://www.bch.org.uk/appeal/donate

Donate to the 3D cardiac printing program

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

You can learn a lot about the future of healthcare by watching how a single pill gets made. From a small office in London, we sit down with Prof Alvaro Goyanes, co-founder and CEO of FabRx, to unpack how 3D printed pharmaceuticals are turning personalized medicine from an idea into a working system. If you’ve ever wondered why patients still get forced into a handful of standard doses, this conversation shows what changes when medicine becomes software-driven and printable on demand.

We talk about what FabRx is building, why they’ve stayed deeply research-led while pushing toward clinical application, and how partnerships with hospitals are translating 3D printing into real studies. We also get specific about the compounding pharmacy workflow: “pharma ink” syringes prepared ahead of time, doses selected in software, and tablets printed with controls that reduce manual steps and help cut inconsistency. It’s a practical look at personalized drug manufacturing for therapies that need flexible dosing across pediatrics, elderly care, hormones, and more.

Quality is the backbone of everything here, so we dig into traceability, weighing each unit, pressure-sensing to catch extrusion problems early, camera systems that verify prints, and where AI inspection and near-infrared methods fit in. We zoom out to the policy layer, including the UK’s move toward distributed point-of-care manufacturing and how regulators in Europe and the US are beginning to shape guidance for 3D printing in pharmacies. Then we end on a wild but serious frontier: why NASA cares about printing medicines in space, where supply chains and gravity don’t cooperate.

If you care about personalized medicine, 3D printing in healthcare, and the future of compounding pharmacies, hit subscribe, share this with a friend in pharma or medtech, and leave a review telling us what application you want to see next.

About Our Guest:

Alvaro Goyanesis the co-founder and CEO of FABRX, the first company dedicated to developing 3D printing technology for the fabrication of personalized medicines and medical devices. He is also an Honorary Associate Professor at University College London- School of Pharmacy (UK) and an Associate Professor at the Faculty of Pharmacy, University of Santiago de Compostela (Spain).
A pioneer in the field, Alvaro was among the first researchers to explore the potential of 3D printing for manufacturing oral dosage forms and medical devices. Recognized as a world expert in 3D-printed medicines, he has been listed among the World's Most Highly Influential Researchers by Web of Science for six consecutive years since 2019.
Alvaro holds a PhD in Pharmaceutics from the University of Santiago de Compostela and previously worked as a Registered Pharmacist for three years, giving him firsthand insight into the needs of community pharmacy.

Show notes: Coming soon

YouTube: Coming soon

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

Neurotech is the category most investors whisper about and then walk away from: too technical, too regulated, too slow. We wanted to talk to someone who leans in anyway, so I sat down with Varun Turlapati, founder of Chanakya Capital, to hear how he’s building an early-stage fund dedicated to neurotech devices and why he thinks the “long horizon” objection often misses what’s actually happening on the ground.

We unpack Varun’s path from software engineering into venture capital, including the mindset shift from analysis paralysis to fast iteration with smart guardrails. From there, we widen the frame on what neurotech means. Yes, brain-computer interfaces matter, but we also get into neuromodulation, bioelectronics, and the nervous system as the body’s command network, linking the brain, gut, and heart, and addressing disease. That lens turns “niche” into “everyone with a brain,” and it changes how you think about markets, clinical impact, and investable product strategy.

Varun also shares the practical mechanics of deep tech investing: how he triages an 80+ company pipeline, separates “interesting” from “investable,” and brings in PhD scientists, physicians, and specialist advisors to evaluate clinical workflows and real differentiation. We dive into real examples across neuroprosthetics, Alzheimer’s, ADHD, and autism wearables, and a smart shunt for hydrocephalus, plus how regulatory signals like Breakthrough Device Designation can reshape the risk profile.

If you care about neurotech startups, medical devices, FDA pathways, or where venture capital goes after AI becomes commoditized, this conversation will sharpen your evaluation of both science and execution. Subscribe to Lattice, share this with a founder or investor who’s curious about neurotech, and leave a review with the biggest question you still have about building in this space.

Show notes: https://3dheals.com/episode-110-neurotech-investing-with-varun-turlapati-chaanakya-capital/

YouTube recording: coming soon

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

We track the biggest healthcare 3D printing stories from March 2026, from bioprinted organs and sustainable bioinks to FDA-cleared implants and hospital point-of-care wins. We also look at how 3D printed cancer tools, training models, microrobots, and AI quality control are moving from research into real clinical and manufacturing workflows.
• bioprinted uterus model for preterm labor drug testing and future personalization
• ENLIGHT pancreas project using volumetric bioprinting and long viability gels for diabetes research
• vascularized adipose tissue implants for soft tissue repair and breast reconstruction
• Singapore biofabrication roadmap focused on sustainable biomaterials and circular supply chains
• FDA 510(k) cleared titanium spinal implant plus trends in lumbar cage materials and coatings
• EU MDR certified denture manufacturing and implications for scaled dental 3D printing
• 3D printed breast cancer locator improving surgical margins with patient-specific guides
• 3D printed metastasis research platform showing fibroblast protection in blood flow stress
• brain phantoms and beating heart simulators for realistic surgical training
• bioprinted cardiac spheroids for studying SARS-CoV-2 heart infection and drug testing
• microrobots, AI defect prediction, volumetric production methods, and micro-scale printers
• hospital-made rehab devices cutting costs and a reality check on AI-driven implants
Please subscribe for more future updates and let us know if anything is missing or incorrect.

Complete show notes, including links to all articles mentioned in this podcast, are here.

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

What happens when a hospital needs a simple part but the supply chain takes weeks or months to deliver it? Dr. Stephan Ryan, physician and co-founder of PolyUnity, set out to solve that problem by helping hospitals produce parts themselves through safe, compliant 3D printing. In this episode, Stephen Ryan shares how early clinical experiences and an academic 3D printing lab evolved into a platform designed to help hospitals manufacture equipment on demand. The COVID pandemic accelerated that vision, exposing major supply chain gaps and pushing the team to rapidly scale production. Stephen Ryan explains how those lessons shaped PolyUnity’s approach to building practical additive manufacturing systems within the realities of healthcare procurement, regulation, and hospital workflows.

Bullet points:

• Defining PolyUnity’s mission to democratize hospital 3D printing with compliant workflows
• The rural hospital supply chain problem that sparked the original research project
• How COVID accelerated real-world production and forced end-to-end process design
• Why post-pandemic red tape returned and how it shaped the software moat
• Bootstrapping a medtech startup in Canada with long procurement cycles
• Building a small team and staying capital efficient through iterative deployment
• Good and "bad" ideas for hospital 3D printing applications
• High-ROI case applications that avoid big spend
• Distributed manufacturing hubs and the practical path toward on-site production
• The wisdom of choosing simple over complexity.
• Post-processing bottlenecks and what are potential solutions.
• Personal transformation from clinician to entrepreneur.

Show notes: https://3dheals.com/teleporting-medicine-with-3d-printing-dr-stephen-ryan-of-polyunity-interview/

Full video interview: https://youtu.be/cO7mTr5GLJ8?si=icmU03OI1cPDZJL9

About our guest:

Dr. Stephen Ryan is a physician, entrepreneur, and the co-founder and Chief Medical Officer of PolyUnity, a Canadian health tech company focused on lowering the barrier for hospitals to adopt 3D printing through itsi3D platform and solutions. His work centers on building software, quality systems, and distributed print capacity so that hospitals can reliably order and receive end use 3D printed parts, from simple fixtures to clinically relevant devices, within existing procurement and regulatory frameworks.

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

We map the biggest shifts in healthcare 3D printing this month, from emissions safety to custom eyewear, implant surfaces, microfluidics, and space-based biomanufacturing. We weigh promise against risk and share where standards and design can close the gap.

• emissions from desktop and industrial printers and why they matter
• safeguards for vulnerable groups and safer materials and testing
• face-scan eyewear, on-demand manufacturing, and fashion collaborations
• implant surface roughness, porosity, coatings, and clinical outcomes
• ceramic, titanium, and PEEK devices for spine, ankle, and CMF
• microfluidics for diagnostics and microneedle vaccines and immunotherapy
• digital microfluidics and 3D cell culture for faster R&D
• microgravity biomanufacturing and what space enables for medicine

See blog post related to this podcast: https://3dheals.com/the-lattice-feb-2026-advanced-devices-custom-eyewear-and-hidden-health-risks-of-3d-printing/

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D

We share how a decade of soft robotics, open APIs, and relentless iteration turned a 3D-printed prototype into a durable, touch-sensing bionic hand used by amputees and robots. Stories of failure, funding, and firsts reveal how speed, sensation, and design choices translate to real lives and real factories.

• early 3D printing wins and durability limits
• shift to soft robotics, silicone overmolding, carbon fiber reinforcement
• founding spark, Ecuador trial, and move from academia to company
• SBIR lifeline, failed crowdfunding, then coverage and clinical validation
• speed, grip force, and touch sensors compared with the market
• open API for control and data streaming in minutes
• robotics crossover in automotive and research labs
• access initiatives via the Ability Fund and global impact
• manufacturing scale plans and ethical boundaries
• practical founder habits, grit, and advice to start now

Please listen to the disclaimer at the end of this podcast

Show notes: https://3dheals.com/aadeel-akhtar-bionic-hands-for-humans-and-robots-the-psyonic-story/

YouTube: https://youtu.be/mDVMRhjXr0w?si=qoZrScjaC6nbiPMJ

About our guest:

Dr. Aadeel Akhtar, CEO of PSYONIC, founded the company to create advanced, accessible bionic limbs after meeting a young girl in Pakistan who was missing a limb. PSYONIC's bionic Ability Hand is the fastest on the market, impact-resistant, and the first to provide a sense of touch. It is also covered by Medicare and is being used by humans and robotics companies globally, including NASA, Meta, Mercedes, and Google. Dr. Akhtar earned a Ph.D. in Neuroscience and an M.S. in Electrical & Computer Engineering from the University of Illinois, along with a B.S. in Biology and an M.S. in Computer Science from Loyola University Chicago. He’s been recognized by MIT Technology Review and Newsweek and secured a 3-shark deal on Shark Tank.

Send us Fan Mail

Support the show

Subscribe to our premium version and support the show.

Follow us:
Twitter
Instagram
Linkedin
3DHEALS WebsiteFacebook
Facebook Group
Youtube channel
About Pitch3D